Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Clinical Cancer Research

• Publication date

  2003-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 12960128
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lung Cancer

  2015cited by this paper
• Death Receptor Ligands, in Particular TRAIL, to Overcome Drug Resistance

  2004cited by this paper
• Fas engagement induces neurite growth through ERK activation and p35 upregulation

  2003cited by this paper
• Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines

  2003cited by this paper
• Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development

  2002cited by this paper
• Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.

  2002cited by this paper
• Novel approaches to the treatment of non-small cell lung cancer.

  2002cited by this paper
• Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil.

  2002cited by this paper
• TRAIL, Fasl and a blocking anti‐DR5 antibody augment paclitaxel‐induced apoptosis in human non‐small‐cell lung cancer

  2002cited by this paper
• Tumor-Infiltrating CD4+ T Lymphocytes Express APO2 Ligand (APO2L)/TRAIL upon Specific Stimulation with Autologous Lung Carcinoma Cells: Role of IFN-α on APO2L/TRAIL Expression and -Mediated Cytotoxicity1

  2002cited by this paper
• Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression

  2002cited by this paper
• Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.

  2001cited by this paper
• Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients.

  2001cited by this paper
• Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

  2001cited by this paper
• Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells.

  2001cited by this paper
• Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.

  2001cited by this paper
• Evidence that the death receptor DR4 is a DNA damage‐inducible, p53‐regulated gene

  2001cited by this paper
• Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer

  2001cited by this paper
• Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)--mediated cytotoxicity by selective up-regulation of TRAIL-R1.

  2001cited by this paper
• Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer.

  2001cited by this paper
• Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.

  2001cited by this paper
• MAPK/ERK Overrides the Apoptotic Signaling from Fas, TNF, and TRAIL Receptors*

  2001cited by this paper
• TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

  2001cited by this paper
• Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.

  2001cited by this paper
• Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells

  2001cited by this paper
• Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach.

  2001cited by this paper
• Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?

  2000cited by this paper
• Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.

  2000cited by this paper
• Phase II study of oxaliplatin (O) and paclitaxel (T) in advanced Non-Small Cell Lung Cancer (NSCLC)

  2000cited by this paper
• Sensitization of human colon cancer cells to trail-mediated apoptosis

  2000cited by this paper
• Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation.

  2000cited by this paper
• TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer.

  2000cited by this paper
• Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460.

  2000cited by this paper
• Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site

  2000cited by this paper
• Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.

  2000cited by this paper
• Differential Localization and Regulation of Death and Decoy Receptors for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Human Melanoma Cells1

  2000cited by this paper
• Human astrocytic brain tumors express APO2L/TRAIL

  1999cited by this paper
• Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

  1999cited by this paper
• Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review).

  1999cited by this paper
• Safety and antitumor activity of recombinant soluble Apo2 ligand.

  1999cited by this paper
• Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma.

  1999cited by this paper
• Expression of FAS (CD95/APO‐1) and FAS ligand in lung cancer, its prognostic and predictive relevance

  1999cited by this paper
• Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients.

  1999cited by this paper
• A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.

  1999cited by this paper
• TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1.

  1999cited by this paper
• Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers.

  1999cited by this paper
• Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis.

  1998cited by this paper
• TRAIL/Apo‐2‐ligand‐induced apoptosis in human T cells

  1998cited by this paper
• Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells.

  1998cited by this paper
• Death receptors: signaling and modulation.

  1998cited by this paper
• An antagonist decoy receptor and a death domain-containing receptor for TRAIL.

  1997cited by this paper
• Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

  1997cited by this paper
• TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL

  1997cited by this paper
• A novel receptor for Apo2L/TRAIL contains a truncated death domain.

  1997cited by this paper
• The Receptor for the Cytotoxic Ligand TRAIL

  1997cited by this paper
• A novel receptor for Apo2L/TRAIL contains a truncated death domain.

  1997cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• Advances in the study of death receptor 5

  2025cites this paper
• TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling

  2024cites this paper
• Molecular signatures in prion disease: altered death receptor pathways in a mouse model

  2024cites this paper
• Nanoparticle-mediated gene delivery of TRAIL to resistant cancer cells: A review

  2024cites this paper
• TRIAL-based combination therapies in cancers.

  2024cites this paper
• MiR-29 and MiR-140 regulate TRAIL-induced drug tolerance in lung cancer

  2024cites this paper
• Apoptosis: a Janus bifrons in T-cell immunotherapy

  2023cites this paper
• Death receptor 5 promotes tumor progression in gastric cancer

  2023cites this paper
• Fate and Efficacy of Engineered Allogeneic Stem Cells Targeting Cell Death and Proliferation Pathways in Primary and Brain Metastatic Lung Cancer

  2023cites this paper
• Enhancer Clusters Drive Type I Interferon-Induced TRAIL Overexpression in Cancer, and Its Intracellular Protein Accumulation Fails to Induce Apoptosis

  2023cites this paper
• TRAIL/S-layer/graphene quantum dot nanohybrid enhanced stability and anticancer activity of TRAIL on colon cancer cells

  2022cites this paper
• TRAIL receptors promote constitutive and inducible IL-8 secretion in non-small cell lung carcinoma

  2022cites this paper
• Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries

  2022cites this paper
• Deep exploration of immune function in EGFR wild-type and mutated lung adenocarcinomas by gene expression profiling: role of TRAIL-R2 (TNFRSF10B) in patient treatment and outcome.

  2022cites this paper
• Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy.

  2021cites this paper
• Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development

  2021cites this paper
• A Magainin-2 like bacteriocin BpSl14 with anticancer action from fish gut Bacillus safensis SDG14.

  2021cites this paper
• Intrinsic and extrinsic pathways of apoptosis: Role in cancer development and prognosis.

  2021cites this paper
• Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids

  2020cites this paper
• Chapter 2 TRAIL-R 3 / R 4 and Inhibition of TRAIL Signalling in Cancer

  2020cites this paper
• TRAIL receptors are differentially regulated and clinically significant in gallbladder cancer.

  2020cites this paper
• Caspase-8: The double-edged sword.

  2020cites this paper
• TRAIL receptor signaling: From the basics of canonical signal transduction toward its entanglement with ER stress and the unfolded protein response.

  2020cites this paper
• The multifaceted role of TRAIL signaling in cancer and immunity

  2020cites this paper
• Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer

  2020cites this paper
• A clinical study on GIST in Babylon

  2020cites this paper
• The SCFSkp2 ubiquitin ligase complex modulates TRAIL-R2-induced apoptosis by regulating FLIP(L)

  2020cites this paper
• Prognostic significance of serum soluble DR5 levels in small-cell lung cancer

  2019influential citation
• Lung Cancer Receptors and Targeting Strategies

  2019cites this paper
• Expression of DR5 and c-FLIP proteins as novel prognostic biomarkers for non-small cell lung cancer patients treated with surgical resection and chemotherapy

  2019cites this paper
• Expression profiles of TRAIL and its receptors in normal, hyperplastic, and malignant endometrial tissues: Hints on endometrial cancer biology

  2019cites this paper
• Diagnostic value of CA‐153 and CYFRA 21‐1 in predicting intraocular metastasis in patients with metastatic lung cancer

  2019cites this paper
• Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer

  2018cites this paper
• Characterising heterogeneous TRAIL responsiveness and overcoming TRAIL resistance in multicellular tumour spheroids

  2018cites this paper
• Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer

  2018cites this paper
• Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC

  2018cites this paper
• Lung cancer: active therapeutic targeting and inhalational nanoproduct design

  2018cites this paper
• University of Groningen Marker discovery for response to ( chemo ) radiation and prognosis in cervical cancer

  2017influential citation
• Case report

  2017influential citation
• Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches.

  2017cites this paper
• Optimizing Multistep Delivery of PEGylated Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand-Toxin Conjugates for Improved Antitumor Activities.

  2017cites this paper
• Ganoderic acid modulating TNF and its receptors: in silico and in vitro study

  2017cites this paper
• TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer

  2017cites this paper
• Bacteriocins BaCf3 and BpSl14 with anticancer and antibiofilm potential from probiotic Bacillus amyloliquefaciens BTSS3 and Bacillus pumilus SDG14 isolated from gut of marine fishes: Enhanced production, Purification and Characterization

  2017cites this paper
• A set of NF- κ B – regulated microRNAs induces acquired TRAIL resistance in Lung cancer

  2017cites this paper
• A set of NF- κ B – regulated microRNAs induces acquired TRAIL resistance in Lung cancer

  2017cites this paper
• Novel antibody-based drugs for PD-L1 and TRAIL-R targeted cancer immunotherapy

  2017cites this paper
• The fibronectin III-1 domain activates a PI3-Kinase/Akt signaling pathway leading to αvβ5 integrin activation and TRAIL resistance in human lung cancer cells

  2016cites this paper
• Potential Role of TRAIL in Metastasis of Mutant KRAS Expressing Lung Adenocarcinoma

  2016cites this paper
• Onto better TRAILs for cancer treatment

  2016cites this paper
• The Janus Face of Death Receptor Signaling during Tumor Immunoediting

  2016influential citation
• Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer

  2016cites this paper
• Triterpenes in cancer: significance and their influence

  2016cites this paper
• Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis.

  2015cites this paper
• TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer

  2015cites this paper
• Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling

  2015cites this paper
• TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model

  2015cites this paper
• The Roles of Non-Coding RNAs in Solid Tumors

  2015cites this paper
• Migration-prone glioma cells show curcumin resistance associated with enhanced expression of miR-21 and invasion/anti-apoptosis-related proteins

  2015cites this paper
• WHO grade related expression of TRAIL-receptors and apoptosis regulators in meningioma.

  2015cites this paper
• Prognostic significance of TRAIL signalling molecules in cervical squamous cell carcinoma

  2015cites this paper
• A set of NF-κB–regulated microRNAs induces acquired TRAIL resistance in Lung cancer

  2015cites this paper
• Raw and thermally treated cement asbestos exerts different cytotoxicity effects on A549 cells in vitro.

  2015cites this paper
• HOOKING TRAIL-R2 TO ¿EDUCATE¿ IMMUNE SYSTEM TO RECOGNIZE CANCER CELLS

  2015cites this paper
• The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis

  2015cites this paper
• Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2

  2014cites this paper
• Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.

  2014cites this paper
• The molecular mechanisms of TRAIL resistance in cancer cells: help in designing new drugs.

  2014cites this paper
• Clinical significance of serum soluble death receptor 5 concentration in locally advanced non-small cell lung cancer patients

  2014cites this paper
• Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Death Receptors DR4 and DR5 in Human Nonmelanoma Skin Cancer

  2014influential citation
• Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer

  2013cites this paper
• Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

  2013cites this paper
• Expression of TRAIL-splice variants in gastric carcinomas: identification of TRAIL-γ as a prognostic marker

  2013cites this paper
• Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma

  2013cites this paper
• Targeting apoptosis pathways in lung cancer.

  2013cites this paper
• Biological significance of a thyroid hormone-regulated secretome.

  2013cites this paper
• An immunohistochemical study of tumour necrosis factor related apoptosis inducing ligand (TRAIL) in lung cancer patients

  2013cites this paper
• Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer

  2013cites this paper
• Embelin and TRAIL Receptor 2 mAb-induced Apoptosis of TRAIL-resistant A549 Non-small Cell Lung Cancer Cells

  2013cites this paper
• A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

  2013cites this paper
• Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).

  2013cites this paper
• TRAIL-induced kinases activation and apoptosis: towards improved death receptor targeted therapy for lung cancer

  2013cites this paper
• Human Cancer Resistance to Trail-Apoptotic Pathway-Targeted Therapies

  2013cites this paper
• Effect of Embelin on TRAIL receptor 2 mAb-induced apoptosis of TRAIL-resistant A549 non-small cell lung cancer cells.

  2013cites this paper
• Monoclonal Antibodies: An Emerging Class of Therapeutics in Non Small Cell Lung Cancer

  2012cites this paper
• Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis.

  2012cites this paper
• TRAIL apoptotic pathway-targeted therapies for NSCLC.

  2012cites this paper
• University of Groningen Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells Azijli,

  2012cites this paper
• Kinome profiling of non-canonical TRAIL signaling reveals RIP1–Src–STAT3-dependent invasion in resistant non-small cell lung cancer cells

  2012cites this paper
• Thyroid hormone receptors promote metastasis of human hepatoma cells via regulation of TRAIL

  2012cites this paper
• Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells

  2012cites this paper
• Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer.

  2011cites this paper
• Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas.

  2011cites this paper
• Understanding the Role of the Death Receptor 5/FADD/caspase-8 Death Signaling in Cancer Metastasis.

  2011cites this paper
• Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.

  2011cites this paper
• Downregulation of endogenous TRAIL and its effect on Downregulation of endogenous TRAIL and its effect on

  2011cites this paper
• The tumor necrosis factor-related apoptosis-inducing ligand and lung cancer: still following the right TRAIL?

  2011cites this paper
• FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.

  2011cites this paper
• Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables

  2011cites this paper
• TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives.

  2010cites this paper